Conjunctivitis in Adults with Atopic Dermatitis Treated with Dupilumab: An Observational Study of Clinical Characteristics, Symptomatology, and Treatment.

ABSTRACT:

Introduction

Conjunctivitis is more prevalent in patients with atopic dermatitis (AD) than the general population, and is the most common adverse event during dupilumab treatment for AD. We aimed to characterize conjunctivitis diagnosed during AD dupilumab treatment and to assess effectiveness of ophthalmic treatments.

Methods

This prospective observational study enrolled adults with AD who received the approved dupilumab regimen in a real-world setting for at least 8 weeks prior to enrollment. At baseline, we compared ophthalmic signs and symptoms in two cohorts of patients who had received dupilumab for similar duration: one with conjunctivitis (group 1) and one with no conjunctivitis (group 2). All patients continued treatment with dupilumab, and group 1 patients received

SUBMITTER: Asbell P 

PROVIDER: S-EPMC12182533 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature